Several presentations at December’s San Antonio Breast Cancer Symposium (SABCS) focused on antibody-drug conjugates (ADCs), a class of therapies that combine antibodies that bind to a unique target (such as trastuzumab/Herceptin) with a cancer-killing drug (chemotherapy).
Theoretically, this allows for toxic drugs to be delivered specifically to cancer cells that express a cancer-specific marker, such as HER2, thereby limiting the broader toxicities of regular chemotherapies.
One ADC that garnered much attention at SABCS is trastuzumab deruxtecan (T-DXd).
T-DXd and DESTINY-Breast03: Overall Survival
DESTINY-Breast03 is the pivotal trial that resulted in the FDA approval of T-DXd as the preferred second-line treatment of HER2+ metastatic breast cancer, displacing T-DM1 to third-line treatment in the United States.
At SABCS this year, investigators for the first time reported data on overall survival (OS), which were published simultaneously in Lancet on December 6. Of note, at this second interim analysis, with more than two years of median follow-up, the median OS was not reached in either the treatment (T-DXd) or control (T-DM1) arm, meaning that more than 50% of patients were still alive in both groups.
However, more patients were alive in the T-DXd arm at 12 months (94.1% with T-DXd versus 86% with T-DM1) and at 24 months (77.4% with T-DXd versus 69.9% with T-DM1). A total of 170 (65%) patients in the T-DXd arm and 138 (52%) in the T-DM1 arm were alive at the July 25, 2022, data cutoff.
While these data sound promising for T-DXd, we can’t really be sure about the extent of the survival benefit of giving T-DXd in the second line of therapy as opposed to the third line because this was not a crossover trial.
Crossover in cancer treatment trials typically occurs when patients in one arm of the trial (e.g., the control arm; in this case, T-DM1) are allowed to receive the treatment drug when their disease progresses. Crossover in cancer studies can be appropriate, but crossover to the treatment drug is not appropriate if the drug being investigated has never demonstrated efficacy.
However, crossover in cancer studies is desired in trials testing whether a drug that has demonstrated benefit in a later line of treatment should be moved to an earlier treatment line, as in this case. Crossover in this instance is critical to better understand the appropriate sequence in which a drug should be given particularly when you consider the toxicity that is associated with T-DXd (see below).
While crossover was not prohibited in this trial when a patient’s disease progressed, it rarely happened. Only 17% of patients in the control arm received T-DXd after their disease progressed compared with 35% of patients in the treatment arm who received T-DM1 after their disease progressed. One likely reason for the limited crossover stems from the fact that most patients included in this trial were from other countries, where T-DXd is not yet an approved drug.
Importantly, DESTINY-Breast09 is currently underway. This is a head-to-head trial comparing T-DXd (with or without pertuzumab) against the current first-line, standard of care (taxane, trastuzumab, and pertuzumab) treatment in the US for metastatic HER2+ breast cancer. Advocates should push to have mandatory crossover in this trial. Without it, we won’t know if moving T-DXd to the first-line setting is better than having it later in treatment after disease progression.
Safety and Toxicity Update for DESTINY-Breast03
The investigators reported no additional toxicity concerns, meaning the updated safety data were consistent with previous findings. However, the previous findings have demonstrated a lot of toxicity.
Compared with T-DM1, patients receiving T-DXd experienced a 12% increase in adverse events of any grade, a 66% increase in serious adverse events, a 205% increase in adverse events causing drug discontinuation, a 74% increase in adverse events causing dose reduction, and a 144% increase in adverse events causing dose interruption. Thankfully, no additional drug-related deaths were reported with the updated data.
Most concerning were the high rates of interstitial lung disease (ILD)/pneumonitis. Fifteen percent of patients treated with T-DXd experienced ILD of any grade compared with only 3% of those receiving T-DM1. This is not new—previous studies have demonstrated similar rates of ILD, including deaths associated with T-DXd.
Sources
- FDA grants regular approval for fam-trastuzumab deruxtecan-nxki for breast cancer
- Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022 Dec 6:S0140-6736(22)02420-5. doi: 10.1016/S0140-6736(22)02420-5. thelancet.com
- Haslam A, Prasad V. When is crossover desirable in cancer drug trials and when is it problematic? Ann Oncol. 2018 May 1;29(5):1079-1081. doi: 10.1093/annonc/mdy116. ncbi.nlm.nih.gov
- Prasad V, Grady C. The misguided ethics of crossover trials. Contemp Clin Trials. 2014 Mar;37(2):167-9. doi: 10.1016/j.cct.2013.12.003.
- Rassy E, Delaloge S. A second-generation antibody-drug conjugate to treat HER2-positive breast cancer. Lancet. 2022 Dec 7:S0140-6736(22)02534-X. doi: 10.1016/S0140-6736(22)02534-X.
- DESTINY-Breast09 trial registration: clinicaltrials.gov/ct2/show/NCT04784715